Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

EdgeRx vs Sprout Health

Two GLP-1 desks, one scoreboard. We put EdgeRx and Sprout Health head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 33 · Grade B

EdgeRx

Visit EdgeRx Full brief →
vs
Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 84 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make EdgeRx a bad call — it's best for men who want a straightforward, disclosed weekly-injectable price on either molecule and value knowing the pharmacy filling the script by name. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
90
Supply Reliability
84
82
Transparency
82
88
Access Breadth
84
92
Clinical Oversight
88
78
Track Record
80
84
EdgeRxBrief Score 84 · 86Sprout Health

Price, coverage & the tracker

EdgeRxSprout Health
Brief Score84/100 (B)86/100 (B)
Semaglutide$229/mo injectable$149/mo
Tirzepatide$299/mo injectable$199/mo
Coverage46 states (excludes Arkansas, Indiana, Minnesota, South Carolina)Not disclosed
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

EdgeRx: First reading — flat weekly-injectable pricing on both molecules, named CMA and named 503A pharmacy.

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.